How does the dual therapy combination of Dolutegravir and Lamivudine (Spegra) compare to traditional triple ART regimens in terms of resistance development?

What factors contribute to Dolutegravir’s high genetic barrier to resistance?
I would appreciate evidence-based explanations, particularly referencing resistance mechanisms, pharmacodynamics, and relevant clinical trial data.